Health
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro – DocWire News
bioRxiv. 2020 Sep 1:2020.08.31.274639. doi: 10.1101/2020.08.31.274639. Preprint.ABSTRACTThere is an urgent need for anti-viral agents that treat
bioRxiv. 2020 Sep 1:2020.08.31.274639. doi: 10.1101/2020.08.31.274639. Preprint.
ABSTRACT
There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold and is a relative of SARS-CoV-2, and identified 108 effective drug…
-
Business22 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Noosa News23 hours ago“There’s No Going Back”: The Grid Meets the Real World in the Initial Trailer for Third ‘TRON’ Movie ‘Ares’
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 6 April 2025
-
Business22 hours agoHere’s a starter portfolio of ASX 200 shares to consider for growth, dividends, and value!